Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin

Journal of the Neurological Sciences

Volumn 278, Issue 1-2, 2009, Pages 107-111

  Nakamura, Katsuya ^a   Yoshida, Kunihiro ^a   Miyazaki, Daigo ^a   Morita, Hiroshi ^a   Ikeda, Shu ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

aminobutyric acid (GABA); Gabapentin; Postural sway study; Spinocerebellar ataxia type 6 (SCA6); The International Cooperative Ataxia Rating Scales (ICARS); Voltage dependent calcium channel (VDCC)

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; GABAPENTIN; IOFETAMINE I 123;

ADULT; AGED; ARTICLE; BODY POSTURE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; FEMALE; HEADACHE; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MALE; OUTCOME ASSESSMENT; POSTURAL SWAY; PRIORITY JOURNAL; RATING SCALE; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SPINOCEREBELLAR ATAXIA TYPE 6; SPINOCEREBELLAR DEGENERATION; SWAY PATH LENGTH; TREATMENT DURATION; UNSTEADINESS;

ADULT; AGED; AMINES; BRAIN; CALCIUM CHANNEL BLOCKERS; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; POSTURAL BALANCE; SPINOCEREBELLAR ATAXIAS;

EID: 58749086706     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.12.017     Document Type: Article

References (21)

1. Bird TD. Hereditary ataxia overview. In: Gene Reviews: Genetic Disease Online Reviews at GeneTest-GeneClinics[database online].[cited 28 February 2008]. Copyright, University of Washington, Seattle, Available at http://www.geneclinics.org/.
2. Schöls L., Bauer P., Schmidt T., Schulte T., and Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 3 (2004) 291-304
3. 1A-voltage-dependent calcium channel. Nat Genet 15 (1997) 62-69
4. 1A-voltage-dependent calcium channel gene. Hum Mol Genet 6 (1997) 1289-1293
5. Sasaki H., Yabe I., and Tashiro K. The hereditary spinocerebellar ataxias in Japan. Cytogenet Genome Res 100 (2003) 198-205
6. 2+ homeostasis and disease. Cell Calcium 28 (2000) 1-21
7. 2+ channels. Annu Rev Cell Dev Biol 16 (2000) 521-555
8. 2δ subunits: differential expression, function, and drug binding. J Bioenerg Biomembr 35 (2003) 639-647
9. McKeown L., Robinson P., and Jones O.T. Molecular basis of inherited calcium channelopathies: role of mutations in pore-forming subunits. Acta Pharmacol Sin 27 (2006) 799-812
10. 2+ channel property by polyglutamine expansion in spinocerebellar ataxia 6. J Neurosci 19 (1999) RC14(1)-14(5)
11. Toru S., Murakoshi T., Ishikawa K., Saegusa H., Fujigasaki H., and Uchihara T. Spinocerebellar ataxia type 6 mutation alters P-type calcium channel function. J Biol Chem 275 (2000) 10893-10898
12. Fogel B., and Perlman S. An approach to the patient with late-onset cerebellar ataxia. Nat Clin Pract Neurol 2 (2006) 629-635
13. Shimojima Y., Hashimoto T., Kaneko K., Yazaki M., Yoshida K., Goto T., et al. Thalamic stimulation for disabling tremor in a patient with spinocerebellar degeneration. Stereotact Funct Neurosurg 83 (2005) 131-134
14. Freund H.J., Barnikol U.B., Nolte D., Treuer H., Auburger G., and Tass P.A. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-a unusual clinical benefit. Mov Disord 22 (2007) 732-735
15. Yabe I., Sasaki H., Yamashita I., Takei A., and Tashiro K. Clinical trial of acetazolamide in SCA6, with assessment using the ataxia rating scale and body stabilometry. Acta Neurol Scand 104 (2001) 44-47
16. Gazulla J., and Tintoré M. The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses 68 (2007) 131-136
17. Gazulla J., and Tintoré M. The P/Q-type voltage-dependent calcium channel: a therapeutic target in spinocerebellar ataxia type 6. Acta Neurol Scand 115 (2007) 356-363
18. 2+ channels by gabapentin. FEBS Lett 528 (2002) 177-182
19. Gazulla J., Errea J.M., Benavente I., and Tordesillas C.J. Treatment of ataxia in cortical cerebellar atrophy with GABAergic drug gabapentin. A preliminary study. Eur Neurol 52 (2004) 7-11
20. Gazulla J., and Benavente I. Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy. Acta Neurol Scand 116 (2007) 235-238
21. Trouillas P., Takayanagi T., Hallett M., Currier R.D., Subramony S.H., Wessel K., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 (1997) 205-211